# A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation

> **NCT00298025** · PHASE4 · COMPLETED · sponsor: **EMD Serono** · enrollment: 185 (actual)

## Conditions studied

- Infertile Women Undergoing Assisted Reproductive Technology (ART)

## Interventions

- **DRUG:** Cetrotide®
- **DRUG:** Antagon ™
- **DRUG:** Recombinant human follicle stimulating hormone (r-hFSH)
- **DRUG:** Human Menopausal Gonadotropin (hMG)
- **DRUG:** Recombinant Human Choriogonadotropin (r-hCG)

## Key facts

- **NCT ID:** NCT00298025
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2004-05
- **Final completion:** 2004-05
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2014-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00298025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00298025, "A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00298025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*